Medical Access and Reimbursement in Anguilla

Currently classified as a strictly controlled substance under national/regional drug‑control enforcement and treated as an illicit/controlled drug with no authorized medical or reimbursed use outside of approved clinical research. Local law‑enforcement reporting shows active policing of controlled‑drug possession and supply in Anguilla, and there is no public record of a legal medical psilocybin program or reimbursement pathway for psilocybin therapy on the island. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of an Anguilla regulatory pathway or insurance reimbursement for MDMA‑assisted therapy; MDMA remains an illicit drug subject to criminal enforcement. #

There is no public record that esketamine (Spravato) has been approved, listed for public reimbursement, or widely adopted as a reimbursed mental‑health therapy in Anguilla. Globally, esketamine is a regulated prescription product with country‑by‑country approvals and safety programmes (e.g., the U.S. FDA approval and REMS for Spravato) and requires certified administration sites; those regulatory approvals do not automatically apply to Anguilla, and no Anguilla government source indicates an established esketamine reimbursement or supply pathway. Clinically, ketamine (racemate) is an established anaesthetic and is listed on the WHO Model List of Essential Medicines, which supports its routine medical availability internationally, but esketamine nasal spray is a distinct regulated pharmaceutical that requires local regulatory approval and infrastructure to be available and reimbursed. # # #
Note: No cited Anguilla regulatory database showing Spravato registration could be found in available public sources; availability would require local regulatory approval and certified administration infrastructure.

Ketamine (the racemic formulation) is widely recognised internationally and used in clinical practice as an anaesthetic and analgesic, and appears on the WHO Model List of Essential Medicines supporting its medical availability in many jurisdictions. #
- Local/regional context (Anguilla): public documentation from Anguilla does not publish a dedicated national formulary or explicit reimbursement policy for ketamine or for off‑label psychiatric use; routine use of ketamine as an anaesthetic in hospitals (operative and emergency care) is consistent with global practice, but there is no public evidence of an organized, reimbursed ketamine‑for‑depression program or national insurance coverage for off‑label psychiatric ketamine in Anguilla. #
- Reimbursement and regulatory detail: no Anguilla government source was identified that lists ketamine for mental‑health reimbursement; where ketamine is used off‑label for psychiatric indications elsewhere it is typically delivered in private clinics without public insurance coverage. Clinicians considering off‑label psychiatric ketamine must follow local licensing for narcotic/controlled medicines, facility safety standards, and importation/possession rules; none of these specific Anguilla regulations for psychiatric ketamine administration or reimbursement were found in public sources during this search. #
Because explicit Anguilla regulatory documents on hospital formularies and reimbursement for ketamine were not publicly located, this entry draws on (A) the WHO listing that supports ketamine’s medical use generally and (B) absence of any public Anguilla program documentation for psychiatric ketamine or esketamine reimbursement.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research in Anguilla; there is no public record of legal therapeutic DMT programs or reimbursement. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research in Anguilla. No public evidence of lawful, reimbursed medical programs or licensing for 5‑MeO‑DMT exists for Anguilla. #

Currently classified as a strictly controlled substance under national/regional drug scheduling and enforcement; there is no documented legal medical or reimbursed ibogaine program in Anguilla and no public evidence of supervised, licensed ibogaine clinics on the island. #

Ayahuasca (DMT‑containing brews) are treated under the same controlled‑substance frameworks as DMT in jurisdictions without explicit religious exemptions; Anguilla has no public record of an authorized religious exemption or regulated therapeutic program for ayahuasca and it should be considered illegal except within an approved research protocol. #

Currently classified as a strictly controlled substance under national drug scheduling; there is no public indication of a licensed, reimbursed medical role for mescaline in Anguilla, nor legal cultivation/supply for therapeutic use outside of narrowly defined religious exemptions in other jurisdictions (none documented for Anguilla). #

Currently classified or treated as prohibited/controlled (phenethylamine/‘research chemical’ class analogues are subject to control) with no authorized medical or reimbursed therapeutic use in Anguilla outside of approved clinical research. Local enforcement actions against controlled drugs have been reported and there is no public evidence of legal, reimbursed access for 2C family compounds. #